Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ha ha - I hear you....but 7.8k PM on news....ridiculous
Close to a million shares traded after market last night......6k this am
SMH
First of many BIG PR’s coming in the next 8 weeks
Page translated:
The innovative drug Vascepa in the field of cardiovascular diseases is piloted in China
20 Jan 2021 14:40:04 Source: Xinhua
On January 19th, Hainan First Age Hospital issued the first prescription for ITE (Twenty Carbon ethyl acetate) for cardiovascular disease- Vascepa capsules. Vascepa is a patented product developed by Anmarin Pharmaceuticals (USA) Co., Ltd. and the first IE prescription drug approved by the U.S. FDA (U.S. Food and Drug Administration). To date, Vascepa has nearly 9 million prescriptions worldwide and has been recommended as a cardiovascular high-risk first- and secondary preventive drug by several guidelines in several overseas countries.
In 2015, Eden Pharmaceuticals received Vascepa's interest in Greater China. On January 17, 2021, Vascepa officially made its debut in the domestic market at the launch of "Four Concessions, Three Synchronizations, New Technologies, New Drugs and New Services" in Boao, Hainan Province. After the conference, eligible patients with cardiovascular disease do not have to go abroad, in Hainan Boao Lecheng International Medical Tourism Advance Zone can use the cardiovascular field innovation drug Vascepa.
Pictured is the launch ceremony of Vascepa's landing in the first district of Lecheng, Hainan Province
Cardiovascular disease is one of the most common diseases in China. Statins are currently the first-line drug to prevent cardiovascular disease, and studies have shown that statins are effective in reducing the relative risk of cardiovascular events by 25%-35%, while still leaving a "residual risk" of 65% to 75% of cardiovascular events. In recent years, triglycerides (TGs) have become a new target for reducing cardiovascular "residual risk". In November 2018, a six-year, 8,179-patient REDEUCE-IT study was published at the American Heart Association's (AHA) annual meeting and later published in the New England Journal of Medicine. Data show that Vascepa can further reduce the "residual risk" of cardiovascular events on the basis of costatin, effectively reducing the risk of five major cardiovascular adverse events (MACE) by up to 25%.
Currently, Vascepa has been recommended for treatment guidelines for atherosclerosis cardiovascular disease (ASCVD) in Europe and the United States, including the American Diabetes Society (ADA), the European Society of Cardiology (ESC) and the European Society for Atherosclerosis (EAS), the National Lipid Association (NLA). Domestically, the China Guidelines for The Prevention of Cardiovascular Disease, issued on November 19, 2020, have also been recommended.
Perplexed to say the least - this would be bad
Eddingpharm is your key way to mainland China.....ETON is a tiny company headquartered in US. Something seems off or there is misinformation floating around.
WTF is going on?
OMG....SPEECHLESS
Amarin could do something like this and it would go a long long way
Try this
Pilot Study Finds Triglyceride Lowering Drug Vascepa May Improve COVID-19 Symptoms via @EverydayHealth https://t.co/EqNfNH3G6P #CardioTwitter #COVID19 #COVIDー19 #coronavirus
— Dr. Deepak L. Bhatt (@DLBHATTMD) January 15, 2021
Just tweeted from BHATT
Pilot Study Finds the Triglyceride Lowering Drug Vascepa May Improve COVID-19 Symptoms
The drug, currently on the market, has been linked to reduced inflammation in people with symptomatic COVID-19.
Becky Upham
By Becky Upham
Last Updated: December 17, 2020
Vascepa pills and coronavirus illustration
Research suggests that the prescription drug Vascepa may help treat the symptoms of mild to moderate COVID-19. Everyday Health
While frontline workers are beginning to get the first round of COVID-19 vaccines, experts agree it will be months before everyone will be protected. In the meantime, researchers continue to look for ways to treat people who have contracted the novel coronavirus.
A new Canadian study presented as a late-breaking clinical trial on December 12 at the National Lipid Association Conference found that the prescription drug Vascepa (icosapent ethyl) shows some promise for treating the symptoms of mild to moderate COVID-19. Those treated with the drug had a 25 percent reduction in the inflammatory biomarker high sensitivity C-reactive protein (CPR), and COVID-19 symptoms were significantly reduced compared with patients who were untreated.
"The large and significant improvement in patient-reported symptoms may provide a safe, well-tolerated, and relatively inexpensive option to impact upon COVID-19 related morbidity, though this finding should be confirmed in a double-blind, placebo-controlled trial," said Deepak L. Bhatt, MD, MPH, the executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart and Vascular Center in Boston, a professor of medicine at Harvard Medical School, and a co-author of the study, during his presentation.
“This is a very interesting study with promising results,” says Jim Liu, MD, a cardiologist at the Ohio State University Wexner Medical Center in Columbus. Vascepa (icosapent ethyl) is a formulation of EPA, which is a kind of omega-3 fatty acid that has been known to reduce inflammation, according to Dr. Liu.
“Using it in this way for COVID-19 is very creative and novel. The results indicate that icosapent ethyl can lower inflammation and, more importantly, improve flu-like symptoms after 14 days,” he says.
What Is Vascepa and How Is It Typically Prescribed?
Vascepa was first approved by the U.S. Food and Drug Administration (FDA) in 2012 for adults with severely high triglyceride levels. It was given an additional approval in 2019 as an add-on therapy to reduce the risk of cardiovascular events such as heart attack and stroke in people whose triglyceride levels are 150 milligrams per deciliter or higher.
Go register that domain for the future......it’s available right now
Thanks for response Lizzy......maybe they are working on something behind the scenes....love to see them get more active.
Do we have a contact with the baker brothers? Does anyone know how to get in front of them on this?
Insider buy would be great right now!!!
23.45
SHADY timing for a downgrade
Goldman Sachs downgrade from 8 to 6
Hats off to you ...... and congrats
Thank you
Where is the COVID script bump that was expected from news last weekend - I figured we would see some additional off label use? Take a few weeks to see some volume? DEEP SIGH
Great idea....how long does this process take?
WTH.....
BHATT SPEAKS - “...formulation matters”
“...oxidation matters”
I’m not sure I’ve ever wanted a TA to become more real then this this one.....We all need some good luck......we all deserve something good to happen
List of outstanding questions
Correct - no ruling.....I’m talking about the LooQ
That’s the conclusion based on the portion of the agenda they showed up on..... lots of volume today - let’s just hope nothing negative is leaking out of that mtg.
LMAO - they are reading your tweets
Did AMRN try to add COVID type language to possible EU label late in process? Is that what has caused the new questions from CHMP?
Who is first analyst to talk about these new developments?
I don’t think anyone wants to see a mention of those letters on this page again. Do not give that clown any relevance. He is dead to most everyone on this page ....with the exception of his cloned accounts that pop up from time to time
What a GREAT point! I never thought about this angle - but this is the root of the problem......they are the real problem.
Yikes -10% on scripts this week....generics already eroding market share quickly
Agree - COVID has many items backed up I believe ..... I would like to see an official extension notification so we have some closure
We need someone in the media to pick this up - fraud being accepted in courts.....if someone could get something published - that also may help?
$3.65
Great Idea
Will double from these levels.....this is a gift
EMA Agenda out - AMRN page 16
icosapent ethyl - EMEA/H/C/005398
indicated to reduce cardiovascular risk as an adjunct to statin therapy.
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 26.03.2020.
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-14-17-september-2020_en.pdf#page16
Many thanks kind sir
What day this week do we know if there are loQI or a recommendation? Do they publish meeting minutes?